Skip to main content
. Author manuscript; available in PMC: 2024 Jan 17.
Published in final edited form as: Semin Radiat Oncol. 2016 May 25;26(4):307–319. doi: 10.1016/j.semradonc.2016.05.001

Table 3.

Ongoing Trials Involving Systemic Approaches With Radiotherapy

Clinical Trial Identifier Cancer Type Regimen Agent and Target Outcomes of Interest
NCT01196390; ongoing, but no longer recruiting HER-2 (+) esophageal ACA Neoadjuvant paclitaxel, carboplatin, and 50.4 Gy (28 fractions)with or without trastuzumab Trastuzumab, anti-HER-2/Neu MAB Disease-free survival, pCR, and toxicity over 8 years. Estimated 591 people enrolled.
NCT02530437; not yet recruiting Esophageal and GEJ ACA Paclitaxel, carboplatin, and 50.4 Gy (28 fractions) with either concurrent or preceding taladegib Taladegib, Hedgehog inhibitor Toxicity and pCR over 10 weeks. Goal enrollment 66 patients.
NCT02375581; currently recruiting Esophageal SCC and ACA Concurrent icotinib with 50–60 Gy (25–30 fractions) Icotinib, anti-EGFR TKI Mortality and toxicity over 2 years. Goal enrollment 130 patients.
NCT02545751; not yet recruiting Metastatic esophageal SCC and ACA Concurrent thymalfasin with 25 Gy (5 fractions) Thymalfasin, stimulates immune system proliferation and differentiation Tumor response over 8 weeks and toxicity and OS over 2 years. Goal enrollment 29 patients.
NCT02381561; not yet recruiting Advanced UGI and lower GI cancers Ropidoxuridine with concurrent radiotherapy (dosing dependent on cancer site) Ropidoxuridine, prodrug for nucleoside analog idoxuridine MTD over 28 days. Goal enrollment 30 patients.
NCT02425605; currently recruiting Advanced HCC Intra-arterial 5-FU with 45 Gy (25 fractions) followed by sorafenib Sorafenib, anti-VEGF-R TKI OS, PFS, and pCR over 36 months. Goal enrollment 47 patients.
NCT01342224; active, but no longer recruiting Locally advanced pancreatic ACA Neoadjuvant telomerase vaccine (GV1001), followed by GM-CSF with gemcitabine and 50.4 Gy (28 fractions). Tadalaf l given throughout treatment and after surgery. Telomerase vaccine (GV1001), peptide subunit of telomerase reverse transcriptase that can generate T-cell response to telomerase Tadalafl, phosphodiesterase inhibitor Toxicity and tumor response over 180 days. 11 enrolled.
NCT02439593; not yet recruiting Locally advanced pancreatic ACA Neoadjuvant FOLFIRINOX followed by concurrent gemcitabine and 50.4 Gy (28 fractions) with or without weekly hyperthermia (40–41C) Localized hyperthermia to 40–41C 1-year OS and safety. Goal 39 patients in each arm.
NCT02405585; currently recruiting Borderline resectable pancreatic ACA Neoadjuvant FOLFIRINOX followed by concurrent gemcitabine and 50.4 Gy (28 fractions) with monthly algenpantucel-l immunotherapy Algenpantucel-L, immunotherapy with human pancreatic cancer cells that contain mouse gene, thereby inducing immune system to recognize and attack cancer cells as foreign 18-month OS, PFS, CR, and safety. Goal 48 patients total.
NCT02349867; currently recruiting Untreated pancreatic ACA Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent gemcitabine, vorinostat, sorafenib, and 50.4 Gy (28 fractions) Vorinostat, histone deacetylase inhibitor Sorafenib, anti-VEGF-R TKI Determine optimal dose and schedule of vorinostat and sorafenib over 18–36 months. Goal 36 patients total.